Jasper Therapeutics, Inc.

What Jasper Therapeutics, Inc. does

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company headquartered at 2200 Bridge Pkwy Suite #102, Redwood City, California. The company is focused on developing therapeutics for chronic mast cell-driven diseases, with its lead asset briquilimab, a humanized aglycosylated monoclonal antibody that blocks stem cell factor (SCF) from binding to the KIT (CD117) receptor, inhibiting downstream signaling and inducing mast cell apoptosis via the Bim-mediated pathway. Jasper is currently conducting clinical studies evaluating briquilimab in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company has also developed the proprietary Jasper c-Kit Mouse™ model, an engineered animal model that overcomes limitations of standard preclinical models for testing KIT inhibitors targeting the human KIT receptor, providing superior translatability to humans.

Jasper's pipeline expanded materially through a announced merger with Kira Pharmaceuticals, adding KP-104 (an anti-C5 monoclonal antibody combined with Factor H as a bifunctional biologic for complement inhibition, in development for IgA nephropathy, C3G, FSGS, and PNH) and KP-701 (an anti-CD79B antibody for autoantibody-mediated disorders). As part of the merger, Kira co-founder Dr. Wenru Song joined Jasper as Executive Vice President and Head of R&D.

Jasper operates as a pre-revenue clinical-stage biotechnology company with no product sales. Its go-to-market motion centers on clinical development, regulatory approval processes, and eventual commercialization through traditional pharmaceutical distribution channels. The company maintains investor relations and clinical trial communications as primary outreach. Jasper has assembled a Scientific Advisory Board featuring globally recognized mast cell and immunology experts from Stanford, Rockefeller, Harvard, UCSF, NIAID, and Fred Hutchinson Cancer Research Center, and a management team with prior IPO and acquisition experience from Portola, Atreca, Aurinia, AstraZeneca, and Millennium/Takeda.

Name

Jasper Therapeutics, Inc.

Legal name

Jasper Therapeutics, Inc.

Website

https://jaspertx.com

Company type

Private

Operating status

Operating

Short description

Jasper Therapeutics is a clinical-stage biotechnology company developing briquilimab, an anti-KIT monoclonal antibody that depletes mast cells to treat chronic urticaria and asthma, with an expanded pipeline in complement and autoantibody diseases via its merger with Kira Pharmaceuticals.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)

akta.pro secondary industry

Bispecific & Multispecific Antibodies (HLAAAAAF)

Keywords

• Monoclonal antibody therapeutics
• Mast cell therapies
• Biopharmaceutical drug development
• Clinical-stage biotechnology
• Anti-KIT antibodies

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Others

Revenue model

1. Pharmaceutical Drug Development and Commercialization: As a clinical-stage biotechnology company, Jasper Therapeutics is focused on developing and commercializing therapeutics for mast cell diseases. The company has not yet generated product revenue and is in the clinical development phase with multiple ongoing clinical studies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Jasper Therapeutics is a clinical-stage biotechnology company developing briquilimab, a targeted aglycosylated anti-KIT (CD117) monoclonal antibody that blocks stem cell factor from binding the KIT receptor to deplete mast cells for the treatment of chronic immunological and inflammatory diseases including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. Following its announced merger with Kira Pharmaceuticals, the pipeline has been expanded to include KP-104 (a bifunctional anti-C5/Factor H complement inhibitor) and KP-701 (an anti-CD79B antibody).

Product overview

Jasper Therapeutics is a clinical-stage biotechnology company developing a pipeline of medicines targeting mast cells and the complement system for immune-mediated diseases. The core product portfolio includes Briquilimab (anti-KIT antibody for mast cell depletion in chronic urticaria and asthma), KP-104 (bifunctional complement inhibitor for nephrology disorders), and KP-701 (anti-CD79B for autoantibody-mediated disorders). The company also offers the proprietary Jasper c-Kit Mouse™ model for preclinical research.

Differentiator

Problem solved

Functional benefit

Products and services

• Briquilimab

Quantifiable outcome

• Demonstrated efficacy and safety profile in patients and healthy volunteers with positive clinical outcomes in CSU, CIndU and asthma

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Kira PharmaceuticalscoreStrategic or Co-development PartnerJasper Therapeutics and Kira Pharmaceuticals announced a merger agreement to combine operations. Kira Pharma co-founder Dr. Wenru Song became Executive Vice President and Head of R&D at Jasper Therapeutics. The merger combines Kira's complement program (KP-104) with Jasper's mast cell programs.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• Escient Pharmaceuticals: Escient Pharmaceuticals is a clinical-stage biotech developing therapies for chronic pruritus and mast cell-driven dermatologic conditions. Its focus on mast cell biology and chronic inflammatory skin disease places it as an emerging peer in adjacent indications to Jasper's CSU and CIndU programs.
• Evommune: Evommune is a clinical-stage biotech developing therapies for chronic urticaria and other immune-mediated inflammatory skin diseases. The company's pipeline focus on chronic urticaria overlaps directly with Jasper's lead briquilimab indication, making it an emerging peer in the CSU competitive landscape.
• Allakos: Allakos is a clinical-stage biotech that has historically pursued mast cell and eosinophil-driven diseases with lirentelimab. While its lead asset was discontinued, Allakos retains mast cell biology expertise and represents an emerging peer in the same mast cell-driven disease category Jasper targets.

Direct peers

• AB Science: AB Science is developing masitinib, a tyrosine kinase inhibitor with activity against KIT, for systemic mastocytosis and other mast cell-driven diseases. The company represents a direct competitor in the mast cell disease therapeutic space, addressing overlapping indications to Jasper's briquilimab.
• Blueprint Medicines: Blueprint Medicines is a direct peer that develops KIT and mast cell biology-targeted therapies, most notably Ayvakit (avapritinib) for systemic mastocytosis and other KIT-driven diseases. Both companies target mast cell-driven diseases with small molecule and biologic approaches, making them the most directly comparable mast cell-focused clinical peer.
• Cogent Biosciences: Cogent Biosciences is developing bezuclastinib, a KIT inhibitor for systemic mastocytosis and other mast cell-driven indications, making it one of the closest direct peers to Jasper in mast cell disease clinical development. Both companies are clinical-stage biotechs focused on KIT receptor biology in inflammatory and proliferative mast cell diseases.
• Celldex Therapeutics: Celldex is developing barzolvolimab, an anti-KIT monoclonal antibody in chronic spontaneous urticaria and other mast cell-driven indications, making it the most directly comparable anti-KIT antibody peer to Jasper's briquilimab. Both companies pursue mast cell depletion via KIT blockade for CSU and related indications.

Broad incumbents

• Sanofi: Sanofi co-markets Dupixent (dupilumab), a leading biologic for asthma and related type2 inflammatory diseases, and is the broader commercial partner for Xolair in some markets. Sanofi represents a broad incumbent competitor across Jasper's core mast cell-driven respiratory indications.
• Genentech (Roche): Genentech and Roche market Xolair (omalizumab), the leading biologic standard of care for chronic spontaneous urticaria. As the established incumbent in CSU, they represent the competitive benchmark Jasper's briquilimab must displace or differentiate against.
• AstraZeneca: AstraZeneca markets Tezspire (tezepelumab), an anti-TSLP biologic approved for severe asthma, and previously employed Jasper's current EVP R&D Wenru Song as Global VP of Immuno-Oncology. AZ is a broad incumbent in the severe asthma space where Jasper's briquilimab is also in development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jasper Therapeutics, Inc.